Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Pancreatic Neoplasms 6Diffuse Intrinsic Pontine Glioma 2Sarcoma 1Pancreatic Adenocarcinoma 1Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoma, B-Cell 1Glioma 1Bone Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7Temozolomide 6Radiotherapy 6fluciclovine F-18 4Topotecan 4fluorodopa F 18 3Biopsy 3niraparib 2abemaciclib 2Standard of Care 2Specimen Handling 2Pemetrexed 2Ketoconazole 2ulixertinib 1temsirolimus 1ribociclib 1posaconazole 1poly ICLC 1pitavastatin 1pembrolizumab 1orludodstat 1lorlatinib 1larotrectinib 1infigratinib 1fisetin 1fimepinostat 1evolocumab 1clevudine 1X-Rays 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Glioma × Gemcitabine × Clear all
NCT04051047 2019-11-27

Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Withdrawn
CNS

Diffuse Intrinsic Pontine Glioma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡